---
figid: PMC9658955__ijms-23-13237-g008
figtitle: LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the
  Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway
organisms:
- vectors
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC9658955
filename: ijms-23-13237-g008.jpg
figlink: /pmc/articles/PMC9658955/figure/ijms-23-13237-f008/
number: F8
caption: Graphic abstract of molecular mechanisms of laminA/C-regulated EMT promoting
  acquired resistance to erlotinib in NSCLC. LaminA/C inhibited the phosphorylation
  of AKT and FGFR to prevent cell proliferation of erlotinib-resistant cells. Meanwhile,
  laminA/C decreased ERK1/2 and c-fos activation and decreased vimentin and ZEB1 expressions,
  resulting in reversing of the process of EMT and improving of erlotinib sensitivity
  in NSCLC with EGFR mutation. By Figdraw (www.figdraw.com).
papertitle: LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the
  Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway.
reftext: Chunsheng Hu, et al. Int J Mol Sci. 2022 Nov;23(21):13237.
year: '2022'
doi: 10.3390/ijms232113237
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: LMNA | epithelial–mesenchymal transition | EGFR-TKI resistance | non-small-cell
  lung cancer
automl_pathway: 0.9559248
figid_alias: PMC9658955__F8
figtype: Figure
redirect_from: /figures/PMC9658955__F8
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9658955__ijms-23-13237-g008.html
  '@type': Dataset
  description: Graphic abstract of molecular mechanisms of laminA/C-regulated EMT
    promoting acquired resistance to erlotinib in NSCLC. LaminA/C inhibited the phosphorylation
    of AKT and FGFR to prevent cell proliferation of erlotinib-resistant cells. Meanwhile,
    laminA/C decreased ERK1/2 and c-fos activation and decreased vimentin and ZEB1
    expressions, resulting in reversing of the process of EMT and improving of erlotinib
    sensitivity in NSCLC with EGFR mutation. By Figdraw (www.figdraw.com).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - EGF
  - AKT1
  - AKT2
  - AKT3
  - FOS
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - MAPK3
  - MAPK1
  - ZEB1
  - ITK
  - SLC22A3
  - Egfr
  - Akt
  - kay
  - bnl
  - btl
  - htl
  - rl
  - Erlotinib
---
